Recombinant Anti-CD44 x Anti-CR3 Bispecific Antibody (IgG-Fv) is formed by an Immunoglobulin G (IgG) and a fragment variable Fv region, in which the Fc of IgG is engineered by KIH. The Fv region of an anti-CD44 antibody variable domain is fused to the C terminal of an IgG of anti-CR3 antibody, or vice versa. The format retains desired characteristics of intact antibodies. This BsAb can recruit macrophages to tumor cells. It is designed for the research of Glioblastoma; Squamous cancer therapy.